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Available online 19 September 2015Although evidence-based medicine indicates that screening
mammograms are currently the sole screening tool that can
lower the breast cancer death rate, the use of mammo-
grams as a screening modality has been widely questioned
during the past decade by public health scholars and
institutional planners. The US Preventive Services Task
Force caused a commotion in 2009 by proposing new rec-
ommendations calling for women older than 50 years to
receive screening once every 2 years, and no full-scale
screening for women older than 75 years. In 2012, British
health units commissioned an independent organization to
perform a detailed analysis of screening policies in the
National Health Service system and submit recommenda-
tions concerning the policy system. In a retrospective
literature review conducted by semiofficial personnel in the
United States, it was suggested that mammogram screening
had not actually achieved the previously reported 25%
decrease in deaths. The report nevertheless supported a
consistent screening policy. In 2014, a nationwide breast
cancer screening study in Canada pointed out that long-
term (25-year) tracking found that annual mammograms
among women in the 40e59 years age group had notConflicts of interest: None.
* Dr Shin-Cheh Chen, Breast Cancer Treatment Group, Chang
Gung Memorial Hospital, Chang Gung University Medical College,




0929-6441/ª 2015, Elsevier Taiwan LLC and the Chinese Taipei Societyreduced the death rate, but led to a 22% overdiagnosis of
invasive breast cancer. The Canadian study consequently
opposed the government’s policy of promoting mammo-
grams for all women, which induced widespread criticism
among medical experts, particularly among specialists in
diagnostic radiology, who pointed out that the effective-
ness of screening cannot be determined solely on the basis
of changes in the death rate in the population as a whole.
Other criticisms were that the study cited erroneous data
and that, because the authors were not frontline doctors in
contact with patients, they could not appreciate public
sentiment. Based on his personal involvement in the
Swedish Two County Trial, the domestic expert Professor
Chen Hsiu-Hsi (Graduate Institute of Public Health, National
Taiwan University) has published several papers on the
effectiveness of service-based mammogram screening, and
has proposed that customized screening policies be
formulated on the basis of individual factors such as breast
cancer genes and family history.
It must be admitted that the effectiveness of screening
has declined with the advances in update treatment mo-
dalities (including chemotherapy, targeted therapy, new
surgical technique, and radiotherapy). In addition, the
growth of health education and the promotion of mam-
mograms have increased women’s awareness of breast
cancer, which has often encouraged them to select other
screening tools and thereby reduce the general mammo-
gram participation rate.
The following is a survey of existing and possible future
screening tools.of Ultrasound in Medicine. Open access under CC BY-NC-ND license.
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indicates that mammography is the currently the sole
screening tool that can lower the death rate from breast
cancer, and according to an independent British report and
joint analysis by the American Cancer Society and the
Journal of the American Medical Association in 2014 sug-
gesting that mammograms can reduce the death rate by
20%, they also have a roughly 20% overdiagnosis rate. The
combined results of various analyses reveal that mammo-
grams reduce the death rate by 15% among women under
the age of 50 years who receive screenings, and decrease
the death rate by a relatively high 32% among women aged
60e69 years; however, they offer no benefit for women
over the age of 70. The Health Promotion Administration
provides screenings to the general public; women in the
45e49 years age group can receive one free mammogram
every 2 years, whereas women in high-risk groups (such as
those whose first-degree family members have had breast
cancer) receive one free mammogram every 2 years from
the age of 40.
Meanwhile, a molecular analysis of breast cancer has
revealed that the estrogen receptor (ER) negative form of
breast cancer is more difficult to discover through
screening mammography than the ER positive form (35.1%
vs. 51.2%), and survival after screening is relatively high
among those with ER negative tumors.
At present, mammogram screening recommendations
include different screening options and intervals depending
on the individual’s degree of risk. The public are fully
informed of the benefits of screening, and also that a
certain percentage of women must receive biopsies at
follow-up appointments, and may even require surgery.
2. Breast magnetic resonance imaging (MRI). Most rele-
vant organizations, including the American Cancer Society,
recommend that women who have a lifetime breast cancer
risk of 20e25% should undergo a breast MRI at least once
each year. However, breast MRIs are not recommended for
women who have only dense breast tissue. This is because,
although MRIs can dramatically increase the breast cancer
detection rate of approximately 5e10/1000) and have
extremely high sensitivity, their specificity is relatively low
with a certain percentage of false positive results. In
addition, the recall rate can be as high as 15%, imaging time
is long (although fast MRI devices have been developed),
and patients report that MRI examination gives an oppres-
sive, claustrophobic impression. As a result of these draw-
backs, breast MRI examinations are currently only given to
women of high-risk groups. The percentages of women in
Taiwan with BRCA 1 and 2 mutations are very low, and a
family history of breast cancer is thought to increase risk by
only 17%. As a result, conditions are not ripe for the MRI
screening of women in Taiwan belonging to high-risk
groups.
3. Digital breast tomosynthesis (DBT). Permission was
granted in 2011 for the use of DBT to detect breast cancers
without calcifications. It has been found that imaging from
the conventional angles, and taking images in layers
0.5 mm thick, can reduce the influence on results of high-
density breast tissue. However, when imaging is per-
formed at relatively low radiation levels, with each breast
receiving a dose of approximately 3 mGy, the calcification
detection rate can be relatively poor. Nevertheless, thebenefit of DBT is that it can reduce the recall rate by
15e29%, while increasing the breast cancer detection rate
to 1.0e2.7/1000. Although DBT does not require forceful
compression of the breasts, the imaging time is long and
movements by the patient may degrade image quality. As a
result, a conventional mammogram is often needed as well.
Apart from an increased radiation dose, DBT images also
require longer time for interpretation by doctors. At pre-
sent, although large-scale studies have verified the use-
fulness of DBT as a means of screening, this method has not
yet obtained approval from the US Food and Drug
Administration.
4. Dual-energy contrast-enhanced spectral mammog-
raphy. This technique involves the injection of a contrast
agent containing iodine, after which the patient’s breasts
are subjected to both low- and high-energy scans, yielding
both conventional mammograms and images showing the
presence of the contrast agent, after subtraction of the
soft-tissue signals. The latter images can provide a high-
contrast view of a malignant tumor that helps in deter-
mining its characteristics and diagnosis. This method can
increase the detection rate, reduce the recall rate, and
resolve the low sensitivity problem of conventional mam-
mograms in women with dense breast tissue. However,
because of its high cost, the application of this method of
screening is currently not feasible.
5. Functional breast imaging (molecular breast imag-
ing). This method, which uses similar principles to those of
positron emission tomography imaging, involves the injec-
tion of 20e25 mGy TC-sestamibi to facilitate imaging. The
method is not affected by breast tissue density, and can
enhance both sensitivity and the positive detection rate.
However, the method has poor sensitivity to small tumors
(<1 cm) and also involves a certain amount of radiation
exposure (approximately 3 mGy, compared with 7.5 mGy
for regular mammograms). Thus far, there has been little
research verifying the practicality of this screening
method.
6. Automated whole breast ultrasonography. In 2012,
the US Food and Drug Administration approved the first fully
automated breast ultrasound device (Somo-V ABUS, U-sys-
tem), which can be used as an auxiliary screening tool for
women with dense breast tissue who have also received
mammograms. After technique improvement, the scanning
interface is curved to meet ergonomic requirements. Usu-
ally, each breast is scanned three times, and each scan
requires only 1 minute. After scanning, computer process-
ing yields ordinary breast ultrasound images and cross
section (C-plane) images. However, although this device
can save time as some of the detection work is performed
by a computer-aided system, its sensitivity is reportedly
low. Also, when a tumor focus is discovered, conventional
breast ultrasonography and perhaps biopsy will be required
to provide confirmation, which will increase the recall rate
and the chance of false positive results. Although use of this
type of device has the advantages of less chance of human
error and short imaging time, the most recent research
results from Somon-Sight indicate that it increases the
breast cancer detection rate only to 1.9/1000. Extensive
research is therefore required to verify whether automated
scanners can replace conventional breast ultrasound as an
auxiliary to mammograms.
122 S.-C. Chen7. Handheld breast ultrasonography. Breast ultrasonog-
raphy is indisputably a more important diagnostic tool than
mammography when breast tumors have been discovered
by physical examination. Nevertheless, no large-scale
research has thus far verified the effectiveness of ultraso-
nography as a means of breast cancer screening. As a
result, no firm conclusions can be made as to the value of
breast ultrasonography as an auxiliary tool after
mammography in women with dense breast tissue. How-
ever, many nonprospective studies have verified that breast
ultrasonography can be useful in screening, and it has a
breast cancer detection rate of roughly 3/1000 or 3&.
According to 2008 and 2012 reports published in the Journal
of the American Medical Association by a prospective study
conducted by the American College of Radiology
(ACRIN6660), when women in slightly high risk groups
receive breast ultrasonography following mammograms,
the breast cancer detection rate can be increased by 34%.
However, the false-positive rate is also relatively high, and
the positive predictive value3 (PPV3) is 11.4%. However,
when breast ultrasonography is used as an initial screening
tool, the recall rate is 10.7% and the breast cancer detec-
tion rate is 7.7&, results which are acceptable. The state
of Connecticut (USA) enacted a law in 2009 requiring
mammograms to be released to patients with dense breast
tissue. Because of this, many medical centers have sought
to use breast ultrasonography as an auxiliary tool, and
numerous published papers (including those from the 2014
San Antonio Breast Cancer Symposium Conference on
Breast Cancer) have found a detection rate for this method
of approximately 4&, which causes the PPV3 value to in-
crease to roughly 20%.
In Asia, a 2004e2009 prospective study conducted by
Taiwan’s Ministry of Health and Welfare and National
Taiwan University researchers Huang Chun-Sheng and Chen
Hsiu-Hsi and colleagues, divided women 40e49 years of age
into three groups: (1) those who received ultrasound
screening during the 1st and 3rd years, and mammograms
during the 2nd and 4th years; (2) those who received mam-
mograms during the 1st and 3rd years and breast ultraso-
nography during the 2nd and 4th years; and (3) no
intervention group. Although the mammogram detection
rate, which averaged 3.1& per year, was greater than the
breast ultrasonography detection rate of 1.7& per year, forinvasive breast cancer, the two methods had detection
rates of 6.2& and 5.1&, respectively, over a 2-year period,
and were not statistically significantly different.
In a similar Japanese study involving women aged 40e49
years, women in the control group received mammograms,
whereas women in the experimental group received both
mammograms and breast ultrasonography. The preliminary
results of the study indicated a greater cancer detection
rate and higher sensitivity for breast ultrasonography than
mammograms.
In spite of the foregoing accomplishments, breast ul-
trasonography is less preferred because of its relatively
high rate of false positive results, the excessive need for
biopsies, the relatively low PPV3 value, long operating
time, and high cost (when performed by a physician).
However, with regard to the first three issues, appropriate
training, evaluation, and certification of ultrasound oper-
ators (including both technicians and doctors) will increase
the breast ultrasonography detection rate, reduce false
positive results, and lessen the need for biopsies. At the
same time, relevant medical associations should find a way
to unify and standardize breast ultrasound terminology.
The detection rate can also be improved by shifting the
focus of breast ultrasonography and assessment courses to
screening issues that include changes in the anatomy of
normal breasts, ultrasound appearance of nonmass-like
breast lesions, and detection of calcifications in breast ul-
trasonography. As for the problems of operating time and
cost, qualified technicians can fill in for doctors, thus
reducing usual examination times to within 20 minutes and
reducing costs.
The following conclusions were made: (1) No perfect
screening tool exists as yet, and use of any one individual
screening tool in isolation is clearly inadequate; (2)
women should be informed ahead of screening about the
advantages and disadvantages of screening, including the
sensitivity of each screening tool, the possibility of being
called back for biopsy, and the benefits and risks associ-
ated with a diagnosis of breast cancer after screening, as
well as the reduction in death rate, overdiagnosis, and the
possibility of overtreatment; and (3) it may be feasible to
give each person a different set of screening options
based on their personal information, individual needs, and
degree of risk.
